01Dec 2023
Karuna Therapeutics' Schizophrenia Treatment, KarXT, Advances as FDA Accepts New Drug Application

Karuna Therapeutics' Schizophrenia Treatment, KarXT, Advances as FDA Accepts New Drug Application

Karuna Therapeutics announced the acceptance of its New Drug Application (NDA) for KarXT (xanomeline-trospium) by the U.S. Food and Drug Administration (FDA). The application, targeting schizophrenia treatment in adults, is set for a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. Positive trial results show improved symptoms without common antipsychotic side effects. KarXT addresses a crucial need for innovative treatments for severe mental illnesses like schizophrenia.

  • #psychiatry

Like

Save

Share